Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 3/29/2024
Go back to Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
February 25, 2021 4:15 PM EST
JMP Securities analyst Jason Butler raised the price target on Karuna Therapeutics Inc. (NASDAQ: KRTX) to $167.00 (from $122.00) while maintaining a Market Outperform rating.
The analyst comments "Karuna announced 4Q20 earnings and provided business updates highlighted by interim Phase 1b healthy elderly volunteer... More